PATENT CLAIM ANALYSIS

Application Number: 15975570
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["564", "336000"]

Abstract:
Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.

Claim (Index 2):
The compound as recited in  claim 1 , which is: or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 93.0
- Lexical Diversity: 1.64474
- Patent Class: 564.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14306396', '12234236', '12234318', '11565451', '11544407']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7240795533965154
- 35 USC 102 Novelty (BERT): 0.5558638911103214
- Combined Prediction Score: 0.7072579871678961
- Mean Citation Score: 313.378958
- Max Citation Score: 357.04333
- Similarity Product: 315.8921739523506

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test